Last reviewed · How we verify
NVGH Vi-CRM197
At a glance
| Generic name | NVGH Vi-CRM197 |
|---|---|
| Sponsor | Novartis |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (PHASE2)
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (PHASE2)
- Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (PHASE2)
- Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) (PHASE2)
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVGH Vi-CRM197 CI brief — competitive landscape report
- NVGH Vi-CRM197 updates RSS · CI watch RSS
- Novartis portfolio CI